Our study also suggests that a deeper understanding of TGF-β actions in both tumour cells and the TME across different cancer types is imperative to identify new therapeutic targets downstream of TGF-β receptors that allow the specific inhibition of TGF-β pro-tumorigenic effects. Here, TGFB1 is linked to neoplasm.